PRINCETON, N.J. and SUZHOU, China, May 21, 2026 -- Transcenta Holding Ltd. (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that its partner Inhibrx Biosciences, Inc. ("Inhibrx") (Nasdaq: INBX) recently reported positive updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). Inhibrx also announced the submission of a Biologics License Application (BLA) to the FDA for ozekibart in conventional chondrosarcoma in April 2026.

Building on this model, Transcenta is expanding its global partner network through additional non-exclusive licensing agreements, helping partners enhance efficiency, lower costs, and increase manufacturing flexibility. Proceeds from these collaborations are reinvested to further strengthen its technology platform and advance its R&D pipeline for next-generation, best-in-class therapeutics.

PRINCETON, N.J. and HANGZHOU, China, December 29, 2025 -- Transcenta Holding Limited (HKEX: 06628) ("Transcenta Therapeutics"), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.

Data showed encouraging results in patients with higher CLDN18.2 expression, regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months.

Transcenta holds the exclusive rights to develop and commercialize ozekibart (INBRX-109) in mainland China, Hong Kong SAR, Macau SAR, and Taiwan region under a license agreement executed through HJB (Hangzhou) Co., Ltd * (杭州奕安济世生物药业有限公司) (“HJB”), a wholly owned subsidiary of Transcenta Holding.